161. |
162. Priporočila Onkološkega inštituta za zdravljenje bolnikov z adenokarcinomom želodcaErik Brecelj, Vesna Zadnik, Neva Volk, Mateja Krajc, Ana Blatnik, Ksenija Strojnik, Nina Boc, Yasmin Marianna Hunt, Gorana Gašljević, Jera Jeruc, Srdjan Novaković, Marko Boc, Franc Anderluh, Martina Reberšek, Borut Štabuc, Irena Oblak, Janja Ocvirk, Ana Jeromen, Zvezdana Hlebanja, Tanja Mesti, Marija Ignjatović, Nežka Hribernik, Ibrahim Edhemović, Gašper Pilko, Rok Petrič, Ajra Šečerov Ermenc, Nada Rotovnik-Kozjek, Vaneja Velenik, Sonja Kramer, Maja Ebert Moltara, Jernej Benedik, 2021, professional article Keywords: adenokarcinom želodca, priporočila, prebavni trakt, multidisciplinarno zdravljenje
Published in DiRROS: 16.12.2021; Views: 1205; Downloads: 536
 Full text (355,48 KB)
This document has many files! More... |
163. |
164. Infiltration processes in karst aquifers affected by large-scale forest disturbancesUrša Vilhar, Mitja Ferlan, Janez Kermavnar, Erika Kozamernik, Aleksander Marinšek, Metka Petrič, Tanja Pipan, Daniel Žlindra, Nataša Ravbar, 2021, published scientific conference contribution abstract Keywords: karst hydrogeology, global environmental changes, large-scale forest disturbances, aquifer recharge, water monitoring
Published in DiRROS: 03.12.2021; Views: 1168; Downloads: 716
Full text (277,79 KB)
This document has many files! More... |
165. |
166. Priročnik za določanje korenin olesenelih rastlinTanja Mrak, Jožica Gričar, Peter Železnik, Hojka Kraigher, 2016, published scientific conference contribution abstract Keywords: določevalni ključi, znanstvene monografije, morfologija rastlin, anatomija rastlin, drobne korenine, EUFORINNO
Published in DiRROS: 03.11.2021; Views: 773; Downloads: 0 |
167. Ectomycorrhiza between Scleroderma Areolatum Ehrenb. and Fagus sylvatica L.Tanja Mrak, Katja Kühdorf, Tine Grebenc, Ines Štraus, Marko Bajc, Nada Žnidaršič, Babette Münzenberger, Hojka Kraigher, 2015, published scientific conference contribution abstract Published in DiRROS: 03.11.2021; Views: 855; Downloads: 281
Full text (1,05 MB) |
168. |
169. Immunotherapy for metastatic non-small cell lung cancer : real-world data from an academic Central and Eastern European centerMarija Ivanović, Lea Knez, Ana Herzog, Mile Kovačević, Tanja Čufer, 2021, original scientific article Abstract: Background. Immunotherapy with immune checkpoint inhibitors (ICIs) recently became the standard treatment for patients with advanced non-small cell lung cancer (NSCLC). Here, we present the first results of a real-world observational study on the effectiveness of ICI monotherapy in patients with advanced NSCLC treated at a single academic center in a Central and Eastern European (CEE) country. Materials and methods. Overall, 66 consecutive patients with advanced NSCLC treated with ICIs in everyday clinical practice, either with first-line pembrolizumab (26 patients) or second-line atezolizumab, nivolumab, or pembrolizumab (40 patients), from August 2015 to November 2018, were included. All data were retrieved from a hospital lung cancer registry, in which the data is collected prospectively. Results. Included patients had a median age of 64 years, most were male (55%), 6% were in performance status >/=2, and 18% had controlled central nervous system metastases at baseline. In first-line, the median progression-free survival (mPFS) was 9.3 months, while the median overall survival (mOS) was not reached. The 1-year overall survival (OS) was 62%. In second-line, the mPFS and mOS were 3.5 months and 9.9 months, respectively, with a 1-year OS of 35%. In the overall population, adverse events of any grade were recorded in 79% of patients and of severe grade (3-4) in 12% of patients. Conclusion. The first real-world outcomes of NSCLC immunotherapy from a CEE country suggest comparable effectiveness to those observed in clinical trials and other real-world series, mainly coming from North America and Western European countries. Further data to inform on the real-world effectiveness of immunotherapy worldwide are needed.
Keywords: non-small cell lung carcinoma, immunotherapy, advanced non-small cell lung cancer, real-world data, Central Europe, Europe, Eastern Europe
Published in DiRROS: 12.10.2021; Views: 978; Downloads: 302
 Link to file |
170. Priporočila Onkološkega inštituta za zdravljenje bolnikov z adenokarcinomom želodca2021, other monographs and other completed works Abstract: V Sloveniji vsako leto zboli zaradi raka želodca okrog 450 bolnikov, od tega ima tri četrtine bolnikov ob postavitvi diagnoze razširjeno ali razsejano bolezen. Zato je pomembno, da imamo razvito sodobno multidisciplinarno zdravljenje. Onkološki inštitut je na poti pridobitve evropske onkološke akreditacije, ki jo podeljuje priznana Evropska organizacija onkoloških inštitutov (OECI), katere član je tudi Onkološki inštitut Ljubljana. Namen tega projekta je razvoj kliničnih poti, ki bodo omogočile celostno obravnavo bolnikov z rakom. Slovenskih priporočil za zdravljenje adenokarcinoma želodca trenutno nimamo, zato smo bili primorani sprejeti te, ki jim bomo sledili na Onkološkem inštitutu. V teh priporočilih, zaradi drugačne narave bolezni, ni zajeto zdravljenje raka ezofagogastričnega stika.
Keywords: rak želodca, adenokarcinom, onkološko zdravljenje, priporočila
Published in DiRROS: 14.09.2021; Views: 1470; Downloads: 383
Full text (983,68 KB) |
